Intrarosa vs Brisdelle: Switching Between Them for Menopause

What Are Intrarosa and Brisdelle, and Why Are They Compared?

These two drugs share only one thing: a menopause indication. Their mechanisms, targets, and side-effect profiles are entirely separate. Women and providers sometimes confuse them because both are marketed as non-estrogen menopause options, but "non-estrogen" covers very different pharmacology.

Intrarosa delivers prasterone, a synthetic version of the naturally occurring hormone dehydroepiandrosterone (DHEA), directly into the vaginal canal. Once inside vaginal tissue, enzymes convert prasterone locally into estrogens and androgens that restore the mucosal lining 1. Systemic absorption is measurable but low enough that serum estrogen levels in clinical trials stayed within the post-menopausal reference range.

Brisdelle contains paroxetine, a selective serotonin reuptake inhibitor (SSRI), at a sub-antidepressant dose of 7.5 mg. It is the only FDA-approved non-hormonal oral drug specifically for moderate-to-severe hot flashes 2. It works centrally, not locally, modulating the thermoregulatory center in the hypothalamus.

Comparing them directly is a bit like comparing an eye drop to a blood-pressure pill: both serve the patient, but for different organs.

Where They Overlap (and Where They Do Not)

The overlap is narrow. Some women have both GSM and vasomotor symptoms, and a clinician might prescribe both simultaneously. The question of switching arises when a woman has been using one and her dominant symptom burden shifts, or when one drug is not tolerated.

How Effective Is Intrarosa for GSM?

Intrarosa is FDA-approved specifically for moderate-to-severe dyspareunia (painful sex) as a symptom of GSM in post-menopausal women. The key trial that supported approval enrolled 557 post-menopausal women and showed statistically significant improvements in dyspareunia severity, vaginal pH, and the proportion of superficial cells on vaginal cytology compared with placebo 1. The dyspareunia responder rate at 12 weeks favored prasterone by a clinically meaningful margin.

What GSM Actually Feels Like

GSM affects an estimated 50 percent or more of post-menopausal women 3, yet fewer than 25 percent seek treatment. Symptoms include vaginal dryness, burning, itching, urinary urgency, and pain during penetration. Unlike vasomotor symptoms, which often improve over time without treatment, GSM tends to worsen progressively as estrogen deprivation continues.

How Long Before Intrarosa Works?

Vaginal cytology improvements in the trial were visible as early as week 2, but meaningful symptom relief for dyspareunia typically takes 8 to 12 weeks of nightly use. Consistency matters. Missing doses regularly delays the mucosal restoration process.

Who Benefits Most

Post-menopausal women whose primary complaint is vaginal dryness, painful sex, or recurrent urinary symptoms linked to vaginal atrophy are the clearest candidates. Intrarosa is also a reasonable choice for breast cancer survivors who cannot use systemic or vaginal estrogen, though oncologists should be consulted given the local androgenic and estrogenic conversion. Women in early perimenopause with intact ovarian function are not the intended population.

How Effective Is Brisdelle for Hot Flashes?

The key low-dose paroxetine trial enrolled 591 menopausal women with moderate-to-severe hot flashes and found that 7.5 mg paroxetine reduced hot-flash frequency by approximately 33 to 37 percent from baseline at weeks 4 and 12, compared with 20 to 24 percent for placebo 2. That translates to roughly 1.5 to 2.0 fewer hot flashes per day compared with placebo. The effect is real but more modest than systemic hormone therapy.

How Brisdelle Compares to Other Hot-Flash Treatments

Systemic estrogen remains the most effective treatment for vasomotor symptoms, reducing hot-flash frequency by 75 percent or more in most trials. Brisdelle sits below that benchmark but is meaningfully better than placebo. For women who cannot or prefer not to use systemic hormones, it is currently the only FDA-approved non-hormonal oral option specifically labeled for this indication. Newer options such as fezolinetant (Veozah), a neurokinin 3 receptor antagonist approved in 2023, are also non-hormonal and may produce larger reductions in hot-flash frequency than Brisdelle.

Onset and Duration

Most women notice a reduction in hot-flash frequency within one to two weeks. The full effect is usually assessed at four weeks. If there is no meaningful response by six weeks at 7.5 mg, the clinical utility of continuing is limited.

Perimenopausal Women and Brisdelle

Perimenopause adds complexity. During the menstrual transition, hot flashes can cluster around hormonal fluctuations tied to the cycle. Brisdelle works around the clock regardless of cycle phase, which is an advantage over some cycle-phase-dependent strategies. The trial enrolled women who were post-menopausal or in late perimenopause, so the evidence is strongest in that group. Women in early perimenopause with regular cycles were not well represented in the key data 2.

A practical framework for life stage: if you are in early perimenopause (cycles still irregular but present) with hot flashes, low-dose paroxetine is used off-label, since Brisdelle's label targets the menopausal population. Post-menopause with hot flashes is where the approved label sits most clearly.

Sex-Specific Pharmacology: What Your Hormones Do to These Drugs

Prasterone (Intrarosa)

The vaginal route is intentional for sex-specific reasons. Post-menopausal vaginal tissue is estrogen-depleted and loses its enzymatic activity over time, but enough steroidogenic enzymes remain to convert DHEA into active sex steroids locally. This intracrinology model means the therapeutic effect is tissue-specific and does not require systemic hormone replacement. Serum DHEA-S levels rise modestly after nightly use, but estradiol and testosterone remain within post-menopausal ranges in clinical measurements 1.

There are no published pharmacokinetic data in premenopausal women using Intrarosa for GSM, because the drug is not indicated in that group.

Paroxetine (Brisdelle)

Women metabolize paroxetine somewhat differently than men. Paroxetine is a CYP2D6 substrate and inhibitor. Women who are CYP2D6 poor metabolizers (approximately 7 to 10 percent of White women and lower rates in East Asian populations) may accumulate higher plasma concentrations at a given dose 4. This pharmacogenomic variability is clinically relevant: if you experience unusually strong SSRI-like side effects at 7.5 mg, poor metabolizer status is worth exploring.

Paroxetine also inhibits CYP2D6, which reduces the conversion of tamoxifen to its active metabolite endoxifen. This interaction is significant enough that Brisdelle is contraindicated in women taking tamoxifen for breast cancer chemoprevention or treatment 5.

Pregnancy, Lactation, and Contraception

This section is required reading if there is any possibility you could become pregnant, or if you are currently breastfeeding.

Intrarosa in Pregnancy and Lactation

Intrarosa is contraindicated in pregnancy. DHEA and its metabolites are active sex steroids, and exogenous androgens and estrogens carry theoretical risks of fetal harm, though specific human teratogenicity data for prasterone are not available. Because Intrarosa is approved only for post-menopausal women, pregnancy is not expected in the target population, but women in late perimenopause who still have any possibility of ovulation should use reliable contraception.

Lactation data are absent. Systemic absorption of prasterone after vaginal administration is low, but because the drug is converted to sex steroids, and because sex steroid transfer into breast milk is possible, breastfeeding is not recommended during use. This situation is largely hypothetical given the post-menopausal indication, but the information belongs here.

Brisdelle in Pregnancy and Lactation

Brisdelle carries a boxed warning for use in pregnancy 5. Paroxetine is associated with an approximately 1.5- to 2-fold increased risk of cardiac septal defects when used in the first trimester, based on epidemiological data. The absolute risk remains low, but paroxetine is classified as Pregnancy Category D (old FDA system) and is one of the few antidepressants specifically avoided in the first trimester whenever possible. Neonatal exposure near delivery is associated with a neonatal adaptation syndrome including jitteriness, feeding difficulty, and respiratory distress.

Paroxetine transfers into breast milk. Infant plasma levels are generally low in published case series, but the manufacturer does not recommend breastfeeding during Brisdelle use, and most lactation authorities advise caution 6.

Contraception: any woman of reproductive potential using Brisdelle should use reliable non-hormonal contraception or discuss the risk-benefit with her prescribing clinician, given the pregnancy risk. The typical Brisdelle patient is post-menopausal, but perimenopausal women who still ovulate occasionally are at some risk.

Who Is Each Drug Right For (and Not Right For)?

Intrarosa Is a Strong Fit If You:

• Are post-menopausal with vaginal dryness, discomfort during sex, or vulvovaginal symptoms as your main concern
• Want localized rather than systemic treatment
• Have contraindications to systemic or vaginal estrogen and prefer an androgen-pathway approach
• Have a breast cancer history and have discussed androgen-based options with your oncologist (evidence of safety in this group is still emerging)

Intrarosa Is Not the Right Choice If You:

• Are primarily bothered by hot flashes or night sweats; it does not address vasomotor symptoms
• Are premenopausal with an intact hormonal cycle
• Are pregnant or breastfeeding

Brisdelle Is a Strong Fit If You:

• Are peri- or post-menopausal with moderate-to-severe hot flashes as your dominant symptom
• Cannot use systemic hormone therapy (cardiovascular history, hormone-sensitive cancer, personal preference)
• Are not taking tamoxifen
• Have no personal or family history of adverse SSRI response that would make even a low-dose trial risky

Brisdelle Is Not the Right Choice If You:

• Have GSM as your main concern; it will not improve vaginal tissue
• Are taking tamoxifen (absolute contraindication due to CYP2D6 inhibition and endoxifen reduction)
• Are pregnant or trying to conceive
• Have a history of SSRI discontinuation syndrome that was severe; even 7.5 mg can cause withdrawal symptoms if stopped abruptly
• Have bipolar disorder without a mood stabilizer on board, as any serotonergic agent can trigger hypomania

Switching Between Intrarosa and Brisdelle: A Practical Guide

No clinical trial has studied a direct switch between prasterone and paroxetine. The following is based on each drug's pharmacology and clinical practice guidance, not a head-to-head dataset.

Switching From Intrarosa to Brisdelle

This scenario typically occurs when a woman whose GSM symptoms are now controlled wants to additionally address escalating hot flashes, or when she decides the daily vaginal insert is not sustainable long-term and hot flashes have become her priority complaint.

Because prasterone has no systemic serotonergic activity, stopping it does not require tapering for neurological reasons. You can discontinue the insert and start Brisdelle 7.5 mg at bedtime the following day. Vaginal symptoms will likely return within four to six weeks of stopping Intrarosa, because the mucosal benefit requires ongoing use. Over-the-counter vaginal moisturizers can bridge that gap if you choose not to restart.

Practical step: confirm you are not on tamoxifen before starting Brisdelle.

Switching From Brisdelle to Intrarosa

This direction happens when hot flashes have eased (often after two to three years post-menopause for many women) but GSM has become the dominant problem. Brisdelle should be tapered rather than stopped abruptly, even at 7.5 mg. A common clinical approach is to halve the dose for one week (which requires splitting the capsule, not ideal with some formulations, so discuss with your pharmacist) or to accept a short taper by taking alternate-day dosing for one week before stopping.

Intrarosa can be started the same day Brisdelle is stopped, since there is no pharmacokinetic interaction between SSRI cessation and vaginal DHEA.

Using Both Simultaneously

Some women benefit from both drugs at once: Brisdelle for hot flashes and Intrarosa for GSM. There is no known pharmacokinetic interaction between vaginal prasterone and low-dose oral paroxetine. A clinician should confirm the full medication list for other interactions before initiating both. The cost and the daily burden of two separate regimens are real practical considerations.

The Evidence Gap: What We Do Not Know

Women have been historically under-enrolled in menopause pharmacology trials, and both of these drugs have limitations in their evidence base that deserve naming.

The Intrarosa key trial 1 enrolled predominantly White post-menopausal women in North America. Outcomes in women of color, women with surgical menopause, and women with premature ovarian insufficiency are not well characterized. Long-term safety data beyond 52 weeks of continuous use are thin.

The Brisdelle key trial 2 similarly enrolled a majority White population. The trial ran only 12 weeks, so durability of the hot-flash response beyond three months is extrapolated from longer paroxetine studies at antidepressant doses, not from the 7.5 mg dose specifically. Whether Brisdelle remains effective after two or three years of continuous use is unknown.

No head-to-head trial between prasterone and paroxetine exists. No trial has formally studied switching protocols. Women making this decision are doing so on the basis of separately conducted placebo-controlled trials, which is standard for drug comparisons but means the relative effect sizes cannot be directly compared.

The Menopause Society (formerly NAMS) addresses both drug classes in its 2023 position statement on menopause hormone therapy and non-hormonal options, noting that local vaginal therapies address GSM specifically and that SSRIs at low dose have a role in VMS management for women who cannot or prefer not to use systemic hormones 7.

ACOG Practice Bulletin 141 on management of menopausal symptoms endorses both categories of treatment but separates them explicitly by indication: vaginal therapies for GSM and low-dose SSRIs for vasomotor symptoms 8.

Cost, Access, and Insurance Realities

Intrarosa does not have a generic equivalent. Monthly cost without insurance runs approximately $350 to $450. Many commercial plans cover it with a prior authorization requirement confirming GSM diagnosis. Medicare Part D coverage varies by plan.

Brisdelle also lacks a widely available generic at the specific 7.5 mg dose, though some pharmacies compound paroxetine at this strength. Monthly cash price is approximately $200 to $300. Prior authorization is common. Some clinicians prescribe generic paroxetine at low dose off-label, which is far less expensive but not FDA-approved for this indication.

Discussing both options with your prescribing clinician and checking formulary status before filling is the most direct way to avoid surprise costs.